hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06384378 id: FP00006640 briefTitle: Systemic and Central Inflammation in AD overallStatus: RECRUITING date: 2023-03-17 date: 2025-12-30 date: 2025-12-30 date: 2024-04-25 date: 2024-04-25 name: The Methodist Hospital Research Institute class: OTHER briefSummary: Inflammation could provide a new focus for therapeutic intervention. In this study, we will measure blood and cerebrospinal fluid (CSF) inflammation biomarkers and compare them to measurements of brain glial activation obtained by positron emission tomography (PET). In addition, we will determine the effect of low-dose interleukin-2 (IL-2) immunotherapy, given over 22 weeks, on these inflammation biomarkers. conditions: Alzheimer Disease studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: OTHER masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 40 type: ESTIMATED name: 11C-ER176 measure: Blood inflammation biomarker levels measure: CSF inflammation biomarker levels measure: Voxel-wise, regional and total brain TSPO VT/fP measured with 11C-ER176 PET sex: ALL minimumAge: 50 Years maximumAge: 86 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Houston Methodist Research Institute status: RECRUITING city: Houston state: Texas zip: 77030 country: United States name: Alireza Faridar role: CONTACT phone: 713-441-1150 email: afaridar@houstonmethodist.org lat: 29.76328 lon: -95.36327 hasResults: False
nctId: NCT06384365 id: 706014-4 briefTitle: Interaction of Inflammation, Taste Perception and Preferences as a Function of Physical Activity and Body Composition overallStatus: RECRUITING date: 2024-04-15 date: 2024-09-30 date: 2025-04-30 date: 2024-04-25 date: 2024-04-29 name: University of Vienna class: OTHER briefSummary: The aim of this study is to investigate whether differences in taste perception and preference behavior can be attributed to inflammatory processes induced by physical activity. The focus will be on sweet taste and the perception of fat. A non-invasive, observational study design will be used. conditions: Taste, Altered studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: CROSS_SECTIONAL count: 66 type: ESTIMATED name: Physical activity measure: Taste sensitivity measure: Taste preference measure: Body composition measure: Low-grade inflammation measure: Oxidative Stress measure: fungiform papillae density sex: ALL minimumAge: 18 Years maximumAge: 45 Years stdAges: ADULT facility: Christian Doppler Laboratory for Taste Research status: RECRUITING city: Vienna zip: 1090 country: Austria name: Barbara Lieder, PhD role: CONTACT phone: +431427770611 email: Barbara.Lieder@univie.ac.at lat: 48.20849 lon: 16.37208 hasResults: False
nctId: NCT06384352 id: YL211-INT-101-01 briefTitle: A Phase I Study to Evaluate the Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors overallStatus: NOT_YET_RECRUITING date: 2024-05-08 date: 2027-04-07 date: 2029-04-07 date: 2024-04-25 date: 2024-04-29 name: MediLink Therapeutics (Suzhou) Co., Ltd. class: INDUSTRY name: Hoffmann-La Roche briefSummary: This is a multicenter, open-label, Phase 1 study. The study will enroll subjects with advanced solid tumors. It consists of three parts. Part 1 is dose-escalation part. In part 1, the safety and tolerability of YL211 in patients with selected advanced solid tumors will be evaluated and the MTD and RED will be determined.
Part 3 is dose-expansion part. In this part, we will further evaluate the safety and efficacy of YL211 at the MTD/RED(s) in patients with selected advanced solid tumors YL211 will be administered intravenously (IV) until criteria of treatment discontinuation are met. conditions: Advanced Solid Tumors studyType: INTERVENTIONAL phases: PHASE1 allocation: NON_RANDOMIZED interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 155 type: ESTIMATED name: YL211 measure: To evaluate nature and frequency of AEs of YL211 in patients with advanced solid tumors according to NCI CTCAE version 5.0 measure: To evaluate nature and frequency of DLTs in part 1. measure: ORR assessed using RECIST version 1.1 measure: To determine the MTD and select the recommended expansion dose(s) (RED(s)) of YL211 in patients with advanced solid tumors measure: To characterize the AUC of YL211 antibody-drug conjugate, YL211 total antibody, unconjugated payload measure: To characterize the Cmax of YL211 antibody-drug conjugate, YL211 total antibody, unconjugated payload measure: To characterize the Ctrough of YL211 antibody-drug conjugate, YL211 total antibody, unconjugated payload measure: To characterize the Tmax of YL211 antibody-drug conjugate, YL211 total antibody, unconjugated payload measure: To characterize the CL of YL211 antibody-drug conjugate, YL211 total antibody, unconjugated payload measure: To characterize the Vd of YL211 antibody-drug conjugate, YL211 total antibody, unconjugated payload measure: To characterize the t1/2 of YL211 antibody-drug conjugate, YL211 total antibody, unconjugated payload measure: To evaluate the anti-drug immune response after treatment with YL211 measure: To evaluate DCR of YL211 in patients with advanced solid tumors using RECIST version 1.1 measure: To evaluate DoR of YL211 in patients with advanced solid tumors using RECIST version 1.1 measure: To evaluate SD of YL211 in patients with advanced solid tumors using RECIST version 1.1 measure: To evaluate TTR of YL211 in patients with advanced solid tumors using RECIST version 1.1 measure: To evaluate PFS of YL211 in patients with advanced solid tumors using RECIST version 1.1 measure: To evaluate OS of YL211 in patients with advanced solid tumors using RECIST version 1.1 measure: To evaluate percent change in target lesion of YL211 in patients with advanced solid tumors using RECIST version 1.1 measure: Characterization of genomic alterations that are predictive of response to YL211 measure: The use of circulating tumor DNA (ctDNA) to monitor response to YL211 treatment sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: NEXT San Antonio city: San Antonio state: Texas zip: 78229 country: United States name: Site Coordinator role: CONTACT lat: 29.42412 lon: -98.49363 hasResults: False
nctId: NCT06384339 id: ID-ClimAct-1 briefTitle: ID-ClimAct. Influence of Social Motives of Clients and Staff on the Social Climate of Secure Settings acronym: ID-ClimAct overallStatus: NOT_YET_RECRUITING date: 2024-05-31 date: 2024-09-20 date: 2024-10-20 date: 2024-04-25 date: 2024-04-29 name: University Psychiatric Clinics Basel class: NETWORK name: University of Basel briefSummary: The social climate in secure settings is an essential element to successful rehabilitation. Previous studies indicate that staff characteristics are a relevant factor contributing to a beneficial social climate. Yet, secure settings form a specific and challenging work environment. Staff members are faced with clients who present a variety of difficult emotional and behavioural problems. Social motives for caring and cooperation can be blocked in a threatening environment, favouring dysfunctional interpersonal dynamics between individuals. This observational study explores the reciprocal influences of social motives between clients and staff on the social climate within secure settings. conditions: Social Environment conditions: Correctional Institutions conditions: Rehabilitation of Criminals conditions: Social Dominance conditions: Interpersonal Relations studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: CROSS_SECTIONAL count: 200 type: ESTIMATED name: CSIV, Social motive name: Interpersonal messages and behavior name: CCS, Social motive measure: Social Climate Perception sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University Psychiatric Clinics Basel, Clinic for Forensics city: Basel state: Basel-Stadt zip: 4002 country: Switzerland lat: 47.55839 lon: 7.57327 hasResults: False
nctId: NCT06384326 id: bagattoni3 briefTitle: Parental Perceptions and Acceptance of Silver Diamine Fluoride in Spain and Italy acronym: SDF overallStatus: COMPLETED date: 2020-09-01 date: 2023-07-01 date: 2023-08-01 date: 2024-04-25 date: 2024-04-25 name: University of Bologna class: OTHER briefSummary: Assessing parental aesthetic acceptability of Silver Diamine Fluoride (SDF) staining is crucial for its potential implementation in paediatric dentistry. This study represents the third part of a wider project initially focused on evaluating SDF aesthetic acceptability in Italy, then comparing it between Spanish and Italian parents conditions: Comparative Study conditions: Aesthetic Perception conditions: Acceptability conditions: SDF studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: CROSS_SECTIONAL count: 501 type: ACTUAL measure: Comparison of SDF's overall acceptance between Spanish and Italian parents measure: Comparison of SDF's specific acceptability in different scenarios of child's behavior between Spain and Italy measure: Parental overall acceptability of SD staining according to demographic background sex: ALL maximumAge: 12 Years stdAges: CHILD facility: Servizio di Assistenza Odontoiatrica per disabili in età evolutiva e di odontoiatria infantile city: Bologna zip: 40125 country: Italy lat: 44.49381 lon: 11.33875 hasResults: False
nctId: NCT06384313 id: NL86266.068.24 briefTitle: Butyrate-enriched Triglyceride and Diabetes Prevention overallStatus: NOT_YET_RECRUITING date: 2024-07-01 date: 2027-09-01 date: 2027-09-01 date: 2024-04-25 date: 2024-04-25 name: Maastricht University Medical Center class: OTHER briefSummary: A body of animal studies as well as observational studies in humans demonstrated that butyrate is one SCFA that has pronounced positive effects on body weight control, inflammation, and insulin resistance. Even though the SCFA hexanoate is less researched, it has been shown to be involved in anti-inflammatory processes. Of note, acute human studies showed that fibre-induced metabolic improvements are linked to higher SCFA levels in the systemic circulation. We previously showed that a butyrate/hexanoate-enriched triglyceride oil enhanced systemic butyrate and hexanoate concentrations for a prolonged time. Yet, it remains to be determined whether a chronic increase in circulating butyrate and hexanoate concentrations translate into long-term benefits. We hypothesize that a chronic increase of butyrate/hexanoate in the circulation may improve host metabolism and metabolic health by improving adipose tissue function, reducing systemic lipid overflow and inflammation thereby increasing peripheral insulin sensitivity in individual with overweight/obesity and prediabetes. conditions: Type 2 Diabetes conditions: PreDiabetes conditions: Obesity studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: BASIC_SCIENCE masking: DOUBLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 48 type: ESTIMATED name: butyrate/hexanoate-enriched triglycerides measure: Peripheral insulin sensitivity measure: hepatic insulin sensitivity measure: adipose tissue insulin sensitivity measure: Energy expenditure (indirect calorimetry) measure: Substrate oxidation (indirect calorimetry) measure: circulating SCFA measure: Faecal SCFA measure: Faecal microbiota composition measure: Circulating hormones such as insulin measure: Circulating metabolites such as glucose measure: body composition measure: body weight measure: Gut permeability sex: ALL minimumAge: 20 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06384300 id: BMSF briefTitle: Financial Incentives and Motivational Intervention to Improve Gastric Cancer Screening in China overallStatus: NOT_YET_RECRUITING date: 2024-08-01 date: 2027-01-31 date: 2027-07-31 date: 2024-04-25 date: 2024-04-25 name: Peking University class: OTHER briefSummary: Gastric cancer, also known as stomach cancer, is a serious disease that affects the stomach. It's one of the most common types of cancer, and sadly, many people die from it each year. But there's hope! We can catch gastric cancer early with a special test called endoscopy. This test helps doctors find cancer or pre-cancerous changes in the stomach early, when it's easier to treat. However, not enough people get this test, especially in places where healthcare isn't easily available. That's why we're doing this study.
Our hope is that by finding out what works best, we can help more people catch gastric cancer early and get the treatment they need. This could save many lives and make a big difference in fighting this disease. conditions: Gastric Cancer studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: HEALTH_SERVICES_RESEARCH masking: NONE count: 5000 type: ESTIMATED name: Financial Incentives name: Motivational Intervention name: Mixed Intervention measure: Primary Outcome 1 measure: Primary Outcome 2 measure: Secondary Outcome sex: ALL minimumAge: 40 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06384287 id: APHP231342 briefTitle: Peripheral Tissue Perfusion in Intensive Care acronym: INPPEREA overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2027-05 date: 2027-05 date: 2024-04-25 date: 2024-04-25 name: Assistance Publique - Hôpitaux de Paris class: OTHER briefSummary: Tissue perfusion has been identified as an early prognosis factor in patients admitted to intensive care. However, little is known about the effects of different hemodynamic interventions performed in clinical routine on peripheral tissue perfusion.
The aim of this work is to study the kinetics of CRT and local skin blood flow following therapeutic intervention (fluid challenge, vasopressor or inotropic drug). conditions: Acute Circulatory Failure studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 180 type: ESTIMATED measure: Skin blood flow variations measure: Capillary refill time measure: Mottling score measure: correlation between Skin blood flow and CRT (baseline and variations) measure: correlation between skin blood flow and Cardiac output measure: correlation between skin blood flow and mean arterial pressure sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06384274 id: NEUniversity briefTitle: The Effect of Emotional Freedom Technique and Virtual Reality Glasses on Anxiety and Vital Signs overallStatus: NOT_YET_RECRUITING date: 2024-10-01 date: 2024-10-01 date: 2025-06-01 date: 2024-04-25 date: 2024-04-25 name: Necmettin Erbakan University class: OTHER briefSummary: The aim of the study was to examine the effects of the emotional freedom technique and virtual reality glasses applied to individuals receiving hyperbaric oxygen therapy for the first time on anxiety and vital signs. The hypotheses of this research are that there is a difference between the emotional liberation technique and virtual reality glasses groups and the control group in terms of anxiety and vital signs. conditions: Anxiety studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: SUPPORTIVE_CARE masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 75 type: ESTIMATED name: Emotional Freedom Technique name: Virtual Reality Glasses measure: State Anxiety Inventory (STAI) measure: Blood Pressure measure: Pulse measure: Respiration measure: Body Temperature measure: Oxygen Saturation sex: ALL minimumAge: 18 Years maximumAge: 60 Years stdAges: ADULT facility: Gülsüm Gürsoy Açikgöz city: Konya state: Meram country: Turkey name: gülsüm GÜRSOY AÇIKGÖZ role: CONTACT phone: 05535553934 email: 2gulsum5@gmail.com lat: 37.87135 lon: 32.48464 hasResults: False
nctId: NCT06384261 id: OV-AML-1231 briefTitle: A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2027-01 date: 2027-06 date: 2024-04-25 date: 2024-04-25 name: OncoVerity, Inc. class: INDUSTRY briefSummary: The goal of this clinical trial is to learn if participants treated with the experimental drug cusatuzumab added to venetoclax and azacitidine works to treat acute myeloid leukemia (AML) compared to venetoclax and azacitidine. Venetoclax and azacitidine are drugs commonly used to treat AML in patients that are unable to receive chemotherapy to treat AML. The main question the clinical trial aims to answer is does cusatuzumab added to venetoclax and azacitidine prolong the length of time participants live compared to venetoclax and azacitidine? conditions: Leukemia, Myeloid, Acute studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 120 type: ESTIMATED name: Cusatuzumab name: Venetoclax name: Azacitidine measure: Overall survival measure: Complete Remission rate (CR) measure: Event-free survival (EFS) measure: Composite CR rate (CRc) measure: Rate of CRh and CRi measure: Duration of CR measure: Time to first CR measure: Rate of minimal residual disease (MRD) negativity in patients achieving CR, CRh, or CRi measure: Proportion of participants proceeding to hematopoietic stem cell transplantation (HSCT) measure: OS in participants undergoing HSCT measure: Incidence of adverse events (AEs), serious adverse events (SAEs), and AEs leading to study drug discontinuation measure: Incidence of dose modifications due to AEs measure: Number of participants with abnormal laboratory test results measure: Incidence of anti-drug antibodies (ADA) and neutralizing antibodies (NAb) measure: Overall survival in subgroups of participants according to specified AML risk stratification models measure: Complete Remission rate sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06384248 id: LTC004-205 briefTitle: Phase II Clinical Study of LTC004 in Patients With Advanced Sarcoma overallStatus: NOT_YET_RECRUITING date: 2024-04-26 date: 2025-12-28 date: 2025-12-28 date: 2024-04-25 date: 2024-04-25 name: Letolab class: INDUSTRY briefSummary: This is a phase II clinical study to evaluate the safety, tolerability and preliminary antitumor activity of LTC004 in patients with locally advanced or metastatic sarcoma；Enrollment of 10 evaluable subjects in Phase I. If ≥2 subjects experience objective remission or SD lasting \>12 weeks, proceed to Phase II to enroll an additional 20 evaluable subjects to further evaluation of the safety and efficacy of LTC004 conditions: Unresectable or Metastatic Sarcoma studyType: INTERVENTIONAL phases: PHASE1 phases: PHASE2 allocation: NON_RANDOMIZED interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 30 type: ESTIMATED name: LTC004 measure: ORR measure: DOR measure: PFS rate measure: OS sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06384235 id: LTC004-203 briefTitle: Phase II Clinical Study of LTC004 in Patients With mCRC overallStatus: NOT_YET_RECRUITING date: 2024-04-25 date: 2025-08-23 date: 2025-08-23 date: 2024-04-25 date: 2024-04-25 name: Letolab class: INDUSTRY briefSummary: This is a phase II clinical study to evaluate the safety and antitumor activity of LTC004 in patients with locally advanced or metastatic CRC，Enrollment of 10 evaluable subjects in Phase I. If ≥2 subjects experience objective remission，proceed to Phase II to enroll an additional 20 evaluable subjects to further evaluation of the safety and efficacy of LTC004 conditions: Locally Advanced or Metastatic CRC studyType: INTERVENTIONAL phases: PHASE1 phases: PHASE2 allocation: NON_RANDOMIZED interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 30 type: ESTIMATED name: LTC004 measure: ORR measure: DOR measure: PFS measure: OS sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06384222 id: 235513 id: NCI-2024-03418 type: REGISTRY domain: NCI Clinical Trials Reporting Program (CTRP) briefTitle: Hyperpolarized (HP) 13C Pyruvate Magnetic Resonance Imaging (MRI) MRI as a Response Monitoring Tool to Neoadjuvant Abiraterone overallStatus: NOT_YET_RECRUITING date: 2024-06-30 date: 2027-07-31 date: 2027-07-31 date: 2024-04-25 date: 2024-04-25 name: Ivan de Kouchkovsky, MD class: OTHER briefSummary: This study will evaluate the use of hyperpolarized 13C MRI (HP 13C MRI) and the HP-derived 13C pyruvate-to-lactate conversion rate constant (kPL) as an early response biomarker in men with treatment-naïve, high-risk, localized or locally advanced prostate cancer receiving neoadjuvant therapy. conditions: High Risk Prostate Carcinoma conditions: Prostate Cancer studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 32 type: ESTIMATED name: Abiraterone acetate name: Prednisone name: Hyperpolarized [1-13C] pyruvate (HP 13C) name: Magnetic Resonance Imaging (MRI) name: Non-investigational radical prostatectomy (RP) name: Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET) PET/Computerized tomography (CT) measure: Mean changes in intratumoral KPL measure: Pathological response rate measure: Proportion of participants with treatment-related adverse events measure: Proportion of participants completing RP measure: Median Time to Biochemical Recurrence measure: Proportion of participants with a >=50% decline in PSA level from baseline (PSA50) response measure: Proportion of participants with a >=90% decline in PSA level from baseline (PSA90) response measure: Mean PSA nadir sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of California, San Francisco city: San Francisco state: California zip: 94143 country: United States name: Maya Aslam role: CONTACT phone: 415-514-8987 email: Maya.Aslam@ucsf.edu name: Ivan de Kouchkovsky, MD role: PRINCIPAL_INVESTIGATOR lat: 37.77493 lon: -122.41942 hasResults: False
nctId: NCT06384209 id: FBplus2024 briefTitle: The Friendship Bench Plus Trial acronym: FB+ overallStatus: NOT_YET_RECRUITING date: 2024-07-01 date: 2026-12-28 date: 2027-02-28 date: 2024-04-25 date: 2024-04-25 name: University of Bern class: OTHER name: University of Zimbabwe name: Swiss National Science Foundation briefSummary: The goal of this randomised controlled trial is to enhance the Friendship Bench intervention with antidepressants in adults with moderate to severe depression. The main questions it aims to answer are:
Participants will be randomly selected and allocated into the control arm or intervention arm. Participants in the control arm will receive six sessions of the Friendship Bench Problem Solving Therapy while those in the intervention arm will receive the Friendship Bench intervention plus Fluoxetine (Sertraline for breastfeeding women). conditions: Major Depressive Disorder conditions: Severe Depressive Episode Without Psychotic Symptoms studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 296 type: ESTIMATED name: Friendship Bench intervention name: Antidepressants -Fluoxetine measure: Treatment response measure: Remission sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of Zimbabwe city: Harare country: Zimbabwe name: Rukudzo Mwamuka, Mbchb,MMed(Psychiatry) role: CONTACT phone: +263777065549 email: ruemwamuka.tsungu@gmail.com name: Jermaine Dambi, PhD role: CONTACT phone: +263773444911 email: jermaine.dambi@friendshipbench.io lat: -17.82772 lon: 31.05337 hasResults: False